Martingale Asset Management L P Vertex Pharmaceuticals Inc Transaction History

Martingale Asset Management L P

$4.27 Billion
Q3 2024

A detailed history of Martingale Asset Management L P transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Martingale Asset Management L P holds 53,327 shares of VRTX stock, worth $24.8 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares

53,327

Previous 62,672 14.91%

Holding current value

$24.8 Million

Previous $29.4 Million 15.57%

% of portfolio

0.58%

Previous 0.64%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $4.3 Million - $4.73 Million	-9,345 Reduced 14.91%	53,327 $24.8 Million
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $2.87 Million - $3.55 Million	-7,316 Reduced 10.45%	62,672 $29.4 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $2.64 Million - $2.88 Million	-6,464 Reduced 8.45%	69,988 $29.3 Million
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $1.66 Million - $1.99 Million	-4,845 Reduced 5.96%	76,452 $31.1 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $200,878 - $215,301	-594 Reduced 0.73%	81,297 $28.3 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $626,010 - $700,652	-1,991 Reduced 2.37%	81,891 $28.8 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $197,411 - $225,200	697 Added 0.84%	83,882 $26.4 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $700,969 - $788,590	-2,453 Reduced 2.86%	83,185 $24 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $5.36 Million - $5.98 Million	19,586 Added 29.65%	85,638 $24.8 Million
Q2 2022 Aug 11, 2022	BUY	$234.96 - $292.55 $3.14 Million - $3.91 Million	13,356 Added 25.35%	66,052 $18.6 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $9.23 Million - $10.9 Million	41,677 Added 378.23%	52,696 $13.8 Million
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $1.01 Million - $1.27 Million	5,687 Added 106.66%	11,019 $2.42 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $14.6 Million - $16.3 Million	-80,314 Reduced 93.77%	5,332 $967,000
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $3.65 Million - $4.31 Million	-19,484 Reduced 18.53%	85,646 $17.3 Million
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $7.76 Million - $9.05 Million	37,505 Added 55.46%	105,130 $22.6 Million
Q4 2020 Feb 10, 2021	SELL	$207.01 - $276.09 $12.5 Million - $16.7 Million	-60,455 Reduced 47.2%	67,625 $16 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $10.8 Million - $12.8 Million	42,151 Added 49.05%	128,080 $34.9 Million
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $16.1 Million - $21.1 Million	71,259 Added 485.75%	85,929 $24.9 Million
Q1 2020 May 11, 2020	BUY	$199.77 - $247.81 $1.89 Million - $2.34 Million	9,452 Added 181.14%	14,670 $3.49 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $999,426 - $1.34 Million	-5,995 Reduced 53.46%	5,218 $1.14 Million
Q3 2019 Nov 13, 2019	SELL	$166.23 - $187.09 $432,198 - $486,434	-2,600 Reduced 18.82%	11,213 $1.9 Million
Q1 2019 May 08, 2019	BUY	$163.73 - $194.7 $491 - $584	3 Added 0.02%	13,813 $0
Q4 2018 Feb 11, 2019	SELL	$151.91 - $192.21 $30,685 - $38,826	-202 Reduced 1.44%	13,810 $2.29 Million
Q3 2018 Nov 09, 2018	BUY	$167.73 - $192.74 $519,962 - $597,494	3,100 Added 28.41%	14,012 $0
Q2 2018 Aug 09, 2018	SELL	$145.72 - $169.96 $319,855 - $373,062	-2,195 Reduced 16.75%	10,912 $0
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $105,968 - $123,813	-699 Reduced 5.06%	13,107 $0
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $68,502 - $77,619	-499 Reduced 3.49%	13,806 $0
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $2.12 Million - $2.32 Million	14,305	14,305 $2.18 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.

Account

Martingale Asset Management L P Vertex Pharmaceuticals Inc Transaction History